Real-world effectiveness and safety of bimekizumab for hidradenitis suppurativa: An ambispective observational study

IF 2.2 4区医学 Q2 DERMATOLOGY Australasian Journal of Dermatology Pub Date : 2024-06-19 DOI:10.1111/ajd.14339

Miguel Mansilla-Polo MD, Martí Pons-Benavent MD, Pablo Fernández-Crehuet MD, PhD, Eva Vilarrasa MD, PhD, Cristina Albanell-Fernández MD, Enrico Morales-Tedone MD, Francisca Rausell-Félix MD, Rebeca Alcalá-García, María Matellanes-Palacios MD, Gemma Martín-Ezquerra MD, PhD, Fernando Alfageme MD, PhD, Cristina Ciudad-Blanco MD, PhD, María Teresa López-Villaescusa MD, Patricia Garbayo-Salmons MD, Antonio Martorell MD, PhD, Begoña Escutia-Muñoz MD, PhD, Fernando Navarro-Blanco MD, Daniel Martín-Torregrosa MD, Carlos Cuenca-Barrales MD, PhD, Alejandro Molina-Leyva MD, PhD, Rafael Botella-Estrada MD, PhD

{"title":"Real-world effectiveness and safety of bimekizumab for hidradenitis suppurativa: An ambispective observational study","authors":"Miguel Mansilla-Polo MD, Martí Pons-Benavent MD, Pablo Fernández-Crehuet MD, PhD, Eva Vilarrasa MD, PhD, Cristina Albanell-Fernández MD, Enrico Morales-Tedone MD, Francisca Rausell-Félix MD, Rebeca Alcalá-García, María Matellanes-Palacios MD, Gemma Martín-Ezquerra MD, PhD, Fernando Alfageme MD, PhD, Cristina Ciudad-Blanco MD, PhD, María Teresa López-Villaescusa MD, Patricia Garbayo-Salmons MD, Antonio Martorell MD, PhD, Begoña Escutia-Muñoz MD, PhD, Fernando Navarro-Blanco MD, Daniel Martín-Torregrosa MD, Carlos Cuenca-Barrales MD, PhD, Alejandro Molina-Leyva MD, PhD, Rafael Botella-Estrada MD, PhD","doi":"10.1111/ajd.14339","DOIUrl":null,"url":null,"abstract":"In this original research, we present the results in terms of effectiveness and safety of bimekizumab for hidradenitis suppurativa in real clinical practice. Results indicated significant improvement in all activity scores and patient-reported outcomes at week 16, including a notable decrease in mean IHS4 from 27.1 to 15.6 (p < 0.001), HS-PGA from 5.1 to 3.2 (p < 0.001), VAS pain from 8.3 to 4.7 (p < 0.001) and DLQI from 21.6 to 12.6 (p < 0.001). Bimekizumab, administered every 2 or 4 weeks, was well-tolerated with no discontinuations and no new safety concerns identified. These findings corroborate the drug's effectiveness and favourable safety profile observed in phase 3 clinical trials, supporting its use in real-world clinical practice for treating HS.","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"65 7","pages":"e198-e202"},"PeriodicalIF":2.2000,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Australasian Journal of Dermatology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ajd.14339","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

In this original research, we present the results in terms of effectiveness and safety of bimekizumab for hidradenitis suppurativa in real clinical practice. Results indicated significant improvement in all activity scores and patient-reported outcomes at week 16, including a notable decrease in mean IHS4 from 27.1 to 15.6 (p < 0.001), HS-PGA from 5.1 to 3.2 (p < 0.001), VAS pain from 8.3 to 4.7 (p < 0.001) and DLQI from 21.6 to 12.6 (p < 0.001). Bimekizumab, administered every 2 or 4 weeks, was well-tolerated with no discontinuations and no new safety concerns identified. These findings corroborate the drug's effectiveness and favourable safety profile observed in phase 3 clinical trials, supporting its use in real-world clinical practice for treating HS.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

比美单抗治疗化脓性扁桃体炎的实际有效性和安全性：一项前瞻性观察研究。

在这项原创研究中，我们介绍了比美单抗在实际临床实践中治疗化脓性扁桃体炎的有效性和安全性。结果表明，在第 16 周时，所有活动评分和患者报告结果均有明显改善，包括 IHS4 平均值从 27.1 显著降至 15.6（p

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Australasian Journal of Dermatology 医学-皮肤病学

CiteScore

3.20

自引率

5.00%

发文量

186

审稿时长

6-12 weeks

期刊介绍： Australasian Journal of Dermatology is the official journal of the Australasian College of Dermatologists and the New Zealand Dermatological Society, publishing peer-reviewed, original research articles, reviews and case reports dealing with all aspects of clinical practice and research in dermatology. Clinical presentations, medical and physical therapies and investigations, including dermatopathology and mycology, are covered. Short articles may be published under the headings ‘Signs, Syndromes and Diagnoses’, ‘Dermatopathology Presentation’, ‘Vignettes in Contact Dermatology’, ‘Surgery Corner’ or ‘Letters to the Editor’.